Evidence map›Paper›PMID 42898130›Full record

ArticleClinical and translational radiation oncology2027

Current role of boron neutron capture therapy in head and neck cancer: insights from 4 years of clinical experience.

Satoshi Takeno, Yuki Yoshino, Teruhito Aihara, Takaki Inui, Tsuyoshi Jinnin, Ichita Kinoshita, Kazuma Kobata, Mari Mukai, Naonori Hu, Akinori Sasaki and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Satoshi TakenoDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Yuki YoshinoDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Teruhito AiharaKansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Takaki InuiDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Tsuyoshi JinninDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Ichita KinoshitaDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Kazuma KobataDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Mari MukaiDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Naonori HuKansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Akinori SasakiKansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Mai NojiriKansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Yasukazu KanaiKansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Tetsuya TeradaDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Shin-Ichi HaginomoriDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Keiji NiheiDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Koji OnoBNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBoron neutron capture therapy (BNCT) was approved in Japan in June 2020 as a curative option for unresectable, locally advanced, or recurrent head and neck cancers. Relevantly, its efficacy and safety in clinical practice should be regularly monitored, particularly regarding its optimal positioning. Therefore, to advance its clinical application, we assessed clinical data on BNCT for head and neck cancers.

methodsWe retrospectively analyzed 285 patients who received initial BNCT between June 2020 and May 2024 with available ≥1 month follow-up data. The primary endpoint was local control (LC); secondary endpoints included progression-free survival (PFS), overall survival (OS), treatment response, and grade ≥ 3 adverse events.

resultsThe 2-year LC, PFS, and OS rates were 41.5%, 26.4%, and 59.2%, respectively. The complete response (CR), partial response (PR), and objective response (CR + PR) rates were 47.0%, 33.3%, and 80.4%, respectively. The cumulative incidence of grade ≥ 3 late adverse events was 14.0% at 2 years, with grade 5 adverse events occurring in 2.1% of patients. No significant differences were observed in LC or PFS among histological type subgroups; however, OS was significantly worse in patients with squamous cell carcinoma (SqCC) than in patients with non-SqCC. Regarding TNM stage at irradiation, radiation therapy at an early disease stage was significantly associated with improved LC.

conclusionsBNCT should be administered during the early disease stages when no other effective treatment options are available. Further studies should determine the factors contributing to treatment efficacy and safety, thereby optimizing multimodal treatment strategies involving BNCT.

Indexed as

Boron neutron capture therapyHead and neck cancerRe-irradiation

Identifiers

PMID42898130
PMCPMC13677289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.